表紙
市場調査レポート

結核 (TB) の予測:主要11市場

Tuberculosis Forecast In 11 Major Markets 2015 -2025

発行 Black Swan Analysis 商品コード 342579
出版日 ページ情報 英文 51 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
結核 (TB) の予測:主要11市場 Tuberculosis Forecast In 11 Major Markets 2015 -2025
出版日: 2015年10月27日 ページ情報: 英文 51 Pages
概要

結核 (TB) は慢性の細菌感染症で、ヒト型結核菌の変異によって引き起こされます。初期の感染部位は肺ですが、肺以外の部位に影響を与えることもあります。結核 (TB) 感染者によるせきやくしゃみなど、飛沫による空気感染で伝染します。

当レポートでは、主要11市場 (米国、フランス、ドイツ、イタリア、スペイン、英国、ブラジル、日本、インド、ポーランド、ルーマニア) における結核 (TB) の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、疾患の概要、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。

図表

イントロダクション

病因

危険因子と予防

疾患の診断

変異:地域/民族別

疾患予後と臨床経過

疾患に関連する主な合併症/特徴

患者数を定量化する手法

結核 (TB) の有病率トップライン

結核 (TB) の特徴

  • 分類
  • 場所
  • 原因となる種
  • 患者の起源

結核 (TB) のケースタイプ

  • 治療成績

結核 (TB) の関連症状

  • HIV
  • 結核薬剤耐性

略語

関連出版

オンラインによる患者ベースのデータベース

患者ベースの製品

オンラインによる価格データとプラットフォーム

参考文献

付録

目次
Product Code: TUBE0011015

Tuberculosis (TB) is a chronic bacterial infection caused by variants of Mycobacterium tuberculosis. Usually affecting the lungs as the primary site of infection, but can affect extra-pulmonary sites also. Transmission occurs by an infected person with active TB, coughing, sneezing or even talking to other people. Droplets of saliva or mucus enter the air and other people are able to inhale the mycobacterium within the droplets.

This report provides the current incidence population for TB across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Poland and Romania) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of TB patient origin status, drug resistance and causative species of TB. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of TB have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for TB include:

  • HIV/AIDS
  • Diabetes
  • Bloody sputum
  • Bone pain

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global TB's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of TB and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on TB's prevalent population.
  • Examination of the incidence of the different causative species for TB.
  • Identify sub-populations within TB which require treatment.
  • Gain an understanding of the specific markets that have the largest number of TB patients.

Coverage

  • U.S.
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
  • Japan
  • U.K.
  • India
  • Poland
  • Romania

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/ Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Incidence for Tuberculosis
  • Features of Tuberculosis
    • Classification of Tuberculosis
    • Tuberculosis Location
    • Tuberculosis-Causing Species
    • Origin Status of Patients with Tuberculosis
  • Tuberculosis Case Type
    • Treatment Outcome of Tuberculosis Case Type
  • Associated Conditions of Tuberculosis
    • HIV
    • Tuberculosis Drug Resistance
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • 1. Incidence of Tuberculosis, total (000s)
  • 2. Incidence of Tuberculosis, males (000s)
  • 3. Incidence of Tuberculosis, females (000s)
  • 4. Diagnosis classification of Tuberculosis, total (000s)
  • 5. Site affected by Tuberculosis, total (000s)
  • 6. Mycobacterium species causing Tuberculosis, total (000s)
  • 7. Origin status of patients with Tuberculosis, total (000s)
  • 8. Case type of patients with Tuberculosis, total (000s)
  • 9. Treatment outcome of new cases of Tuberculosis, total (000s)
  • 10. Treatment outcome of previously treated cases of Tuberculosis, total (000s)
  • 11. HIV in patients with Tuberculosis, total (000s)
  • 12. Miliary Tuberculosis in Tuberculosis patients with HIV, total (000s)
  • 13. Multi-drug resistance in patients with Tuberculosis, total (000s)
  • 14. Any Tuberculosis drug resistance in patients with Tuberculosis, total (000s)
  • 15. Isoniazid resistance in patients with Tuberculosis, total (000s)
  • 16. Abbreviations and Acronyms used in the report
  • 17. USA Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 18. USA Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 19. France Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 20. France Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 21. Germany Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 22. Germany Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 23. Italy Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 24. Italy Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 25. Spain Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 26. Spain Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 27. United Kingdom Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 28. United Kingdom Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 29. Brazil Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 30. Brazil Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 31. Japan Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 32. Japan Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 33. India Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 34. India Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 35. Poland Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 36. Poland Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 37. Romania Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 38. Romania Incidence of Tuberculosis by 5-yr age cohort, females (000s)
Back to Top